Cupron Medical Established as Part of
Recapitalization and Restructuring of Cupron Inc.
February 24, 2010 09:40 AM Eastern Time
RICHMOND, Va.--(EON: Enhanced Online News)--Virginia Life Science Investments, LLC and other investors
have completed a recapitalization and management restructuring of Cupron, Inc., a Delaware corporation established
in 2001, with principal offices in Modi’in, Israel. The transaction provides significant new capital to support the
continued growth and development of Cupron Inc.; as well as the formation and initial capitalization of an
independent new entity, Cupron Medical Inc., a Delaware corporation with principal offices in Richmond, VA.
The transaction also resulted in the formation of a new executive leadership team. Key members of this new team
include Mr. Paul Rocheleau, a seasoned executive in technology development, global materials business leadership,
and venture management, who has been appointed to the dual roles of Chairman of the Board for Cupron Inc. and
Chief Executive Officer of Cupron Medical Inc. Mr. Danny Lustiger, an experienced executive with extensive
operational and financial management experience with technology companies, was appointed as President and Chief
Executive Officer of Cupron Inc. And Mr. Ronald Dziedziula, a 30 year marketing, sales, and operational executive
of the medical device industry, who joined Cupron Medical Inc. as Vice President and General Manager.
Cupron Inc. has developed a robust, patented antimicrobial technology platform that uses a natural, Environmental
Protection Agency (EPA) registered form of Copper (cuprous oxide), providing an effective broad spectrum
antimicrobial with many medical and consumer applications. Cupron technology has also been clinically
demonstrated to have cosmetic benefits such as a reduction in the appearance of wrinkles and related skin
conditions. In addition, Cupron technology has shown early clinical evidence of having a potential positive effect on
wound healing and in tre